Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

PURPOSE: Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lower dose given for...

Descripción completa

Detalles Bibliográficos
Autores principales: DeCensi, Andrea, Puntoni, Matteo, Guerrieri-Gonzaga, Aliana, Caviglia, Silvia, Avino, Franca, Cortesi, Laura, Taverniti, Cristiana, Pacquola, Maria Grazia, Falcini, Fabio, Gulisano, Marcella, Digennaro, Maria, Cariello, Anna, Cagossi, Katia, Pinotti, Graziella, Lazzeroni, Matteo, Serrano, Davide, Branchi, Daniela, Campora, Sara, Petrera, Marilena, Buttiron Webber, Tania, Boni, Luca, Bonanni, Bernardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601429/
https://www.ncbi.nlm.nih.gov/pubmed/30973790
http://dx.doi.org/10.1200/JCO.18.01779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601429/
https://www.ncbi.nlm.nih.gov/pubmed/30973790
http://dx.doi.org/10.1200/JCO.18.01779

Ejemplares similares